Stephens Resumes Repligen (RGEN) at Overweight

Stephens analyst Jacob Johnson resumes coverage on Repligen (NASDAQ: RGEN) with a Overweight rating and a price target of $110.00.

The analyst comments "We view RGEN as one of those unique stocks where a Company led by a best-in-class management team has positioned itself within the right area of a rapidly growing industry. This results in a great story stock coupled with stellar financial results and fundamentals to back it up. This does come at a price as RGEN shares trade at a premium valuation. While we ideally would like to find a cheaper entry point, there appears to be no shortage of momentum in RGEN’s operations. We want exposure to the growing biologics end market and to invest with the RGEN management team. As a result, we are willing to pay up for the opportunity."

For an analyst ratings summary and ratings history on Repligen click here. For more ratings news on Repligen click here.

Shares of Repligen closed at $93.38 yesterday.

You May Also Be Interested In

• Goldman Sachs Starts Rightmove Plc. (RMV:LN) (RTMVY) at Neutral
• Jefferies Starts Athabasca Oil Corp. (ATH:CN) (ATHOF) at Buy
• Wolfe Research Assumes Repligen (RGEN) at Outperform